AngioDynamics (ANGO) - EV/EBITDA Multiple

AngioDynamics Inc. - graphic logo of issuer ANGO

The price action for AngioDynamics, Inc. (ANGO) shown on this chart reflects an EV/EBITDA of 168.80. The business relies on the development of advanced electroporation and vessel cleansing systems. Production facilities operate at maximum efficiency due to the implementation of automated quality monitoring. Revenue stability is ensured by the critical nature of the therapy, rendering demand for the products insensitive to economic fluctuations.

ANGO AngioDynamics Corp: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026

Analytical breakdowns for angiodynamics.com (ANGO)

- stock price and consensus target price:
Stock Quotes AngioDynamics Corp|ANGO - Fair Value Consensus
- market capitalization indicators:
Market Capitalization AngioDynamics Inc.|ANGO - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share AngioDynamics|ANGO - Accounting Capitalization|Market Value to Book Value Ratio angiodynamics.com|ANGO - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Equity Ratio AngioDynamics, Inc.|ANGO - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity AngioDynamics|ANGO - Aggregate Debt Obligations|Debt to Book Value AngioDynamics Inc.|ANGO - Company Long-Term Debts|Company Short-Term Debt AngioDynamics|Quick Ratio angiodynamics.com
- business earnings and investment ratios data:
ANGO - Company Net Income|Expected Profit AngioDynamics, Inc.|ANGO - Price to Earnings Multiple|Projected Price to Earnings AngioDynamics, Inc.|ANGO - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AngioDynamics Inc.|ANGO - Operating income before deduction of amortization|Net earnings per share (EPS TTM) AngioDynamics|ANGO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months angiodynamics.com|ANGO - Earnings per share growth this year|Earnings growth forecast for next year AngioDynamics, Inc.
Summary company analysis:AngioDynamics Corp (ANGO)
Manufactured products of AngioDynamics

Fundamental asset selection requires analyzing business value relative to its ability to generate cash flow. The EV/EBITDA metric compares market capitalization and debt against operating profit before taxes and amortization. For AngioDynamics, Inc. (ANGO), this reflects the value of innovations in bloodless tumor ablation while accounting for production capital intensity. The trajectory of the company's EV/EBITDA value demonstrates a real-time market revaluation of these technological advantages.

Competitors of AngioDynamics, Inc.

Intuitive Surgical Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DHR|Becton Dickinson & Co - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio steris.com STE|West Pharmaceutical Services, Inc. (WST) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BAX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Masimo Personal Health|Stevanato Group Corp (STVN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TFX (Teleflex Incorporated)|Enterprise Value to Operating Income Before Depreciation Ratio MMSI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Envista NVST|Business Value to Operating Income Before Depreciation ICUI|XRAY: Enterprise Value to EBITDA Ratio|LMAT - EV/EBITDA Multiple|AtriCure, Inc. (ATRC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio staar.com|NAGE (ChromaDex Corp.) - EV/EBITDA Multiple|Company Value to EBITDA ZimVie Inc ZIMV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cerus Corp (CERS)|Teknova Inc - Enterprise Value to Operating Income Before Depreciation|Monogram Technologies - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio STSS (Sharps Technology Inc)|INFU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Utah Medical Products Inc. UTMD|KRMD: EV/EBITDA Multiple|Nyxoah S.A (NYXH) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Microbot Medical Inc.|Enterprise Value to Operating Income Before Depreciation PDEX (pro-dex.com)|EV/EBITDA Multiple ZTEK|Elutia Inc (ELUT) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple MLSS (Milestone Scientific Corp)|Total Company Value to Operating Income Before Depreciation Ratio NEXGEL Inc (NXGL)|RVP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Harvard Bioscience Inc.|FEMY: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MHUA|Enterprise Value to EBITDA Ratio POAI|Company Value to EBITDA Callan JMB Corp CJMB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atrion Corporation (ATRI)|neurometrix.com - Enterprise Value to Operating Income Before Depreciation